DDInter1139 DDInter1566
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Flurbiprofen
Flurbiprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Plicamycin
Plicamycin {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Diclofenac
Diclofenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Levomilnacipran
Levomilnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Milnacipran {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Mefenamic acid {u} (Compound) resembles {v} (Compound) Ketoprofen
Ketoprofen {u} (Compound) resembles {v} (Compound) Nepafenac
Nepafenac {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramucirumab
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may lead to a major life threatening interaction when taken with Ramucirumab
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may lead to a major life threatening interaction when taken with Ramucirumab
Mefenamic acid (Compound) resembles Flurbiprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab and Flurbiprofen may lead to a major life threatening interaction when taken with Ramucirumab
Mefenamic acid (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin and Plicamycin may lead to a major life threatening interaction when taken with Ramucirumab
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Mefenamic acid (Compound) resembles Diclofenac (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Mefenamic acid (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Levomilnacipran (Compound) and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound) and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Mefenamic acid (Compound) resembles Ketoprofen (Compound) and Ketoprofen (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab